The DOI matches its Crossref record; 345 of the 345 references it cites were found in a registry or an index.
The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
Open accessAbstract
The P2X7 receptor is a trimeric ATP-gated cation channel found predominantly, but not exclusively, on immune cells. P2X7 activation results in a number of downstream events, including the release of proinflammatory mediators and cell death and proliferation. As such, P2X7 plays important roles in various inflammatory, immune, neurologic and musculoskeletal disorders. This review focuses on the use of P2X7 antagonists in rodent models of neurologic disease and injury, inflammation, and musculoskeletal and other disorders. The cloning and characterization of human, rat, mouse, guinea pig, dog, and Rhesus macaque P2X7, as well as recent observations regarding the gating and permeability of P2X7, are discussed. Furthermore, this review discusses polymorphic and splice variants of P2X7, as well as the generation and use of P2X7 knockout mice. Recent evidence for emerging signaling pathways downstream of P2X7 activation and the growing list of negative and positive modulators of P2X7 activation and expression are also described. In addition, the use of P2X7 antagonists in numerous rodent models of disease is extensively summarized. Finally, the use of P2X7 antagonists in clinical trials in humans and future directions exploring P2X7 as a therapeutic target are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., & Núñez, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.016 · Cited by 2,147
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Burnstock, G. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06930-3 · Cited by 1,852
The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739
Pannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor
Pelegrin, P., & Surprenant, A. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601378 · Cited by 1,431
CD36 is a receptor for oxidized low density lipoprotein
Endemann, G., Stanton, L. W., Madden, K. S., Bryant, C. M., White, R. T., & Protter, A. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50272-1 · Cited by 1,281
Yegutkin, G. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.024 · Cited by 1,154
Altered Cytokine Production in Mice Lacking P2X7Receptors
Solle, M., Labasi, J., Perregaux, D. G., Stam, E., Petrushova, N., Koller, B. H., Griffiths, R. J., & Gabel, C. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006781200 · Cited by 930
Purine and pyrimidine receptors
Burnstock, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6497-0 · Cited by 929
Cited by
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672
The P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267
Ion Channels in Innate and Adaptive Immunity
Feske, S., Wulff, H., & Skolnik, E. Y. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112212 · Cited by 768
Yang, D., He, Y., Muñoz-Planillo, R., Liu, Q., & Núñez, G. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.009 · Cited by 596
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Linden, J., Koch-Nolte, F., & Dahl, G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052406 · Cited by 377
Purine and purinergic receptors
Burnstock, G. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818817494 · Cited by 329
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
Illes, P., Müller, C. E., Jacobson, K. A., Grutter, T., Nicke, A., Fountain, S. J., Kennedy, C., Schmalzing, G., Jarvis, M. F., Stojilkovic, S. S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15299 · Cited by 313
Structural basis for subtype-specific inhibition of the P2X7 receptor
Karasawa, A., & Kawate, T. (2016) · eLife · doi:10.7554/elife.22153 · Cited by 303
Calcium Dynamics as a Machine for Decoding Signals
Giorgi, C., Danese, A., Missiroli, S., Patergnani, S., & Pinton, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.01.002 · Cited by 281
Medicinal chemistry of adenosine, P2Y and P2X receptors
Jacobson, K. A., & Müller, C. E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.001 · Cited by 262
The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells
Borges da Silva, H., Beura, L. K., Wang, H., Hanse, E. A., Gore, R., Scott, M. C., Walsh, D. A., Block, K. E., Fonseca, R., Yan, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0282-0 · Cited by 258
Lüscher, B., Bütepage, M., Eckei, L., Krieg, S., Verheugd, P., & Shilton, B. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00122 · Cited by 255
Burnstock, G., & Knight, G. E. (2018) · Purinergic Signalling · doi:10.1007/s11302-017-9593-0 · Cited by 248
Targeting Cell Death: Pyroptosis, Ferroptosis, Apoptosis and Necroptosis in Osteoarthritis
Yang, J., Hu, S., Bian, Y., Yao, J., Wang, D., Liu, X., Guo, Z., Zhang, S., & Peng, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789948 · Cited by 244
Sluyter, R. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2017_59 · Cited by 235
Self-citationThe microglial ATP‐gated ion channel P2X7 as a CNS drug target
Bhattacharya, A., & Biber, K. (2016) · Glia · doi:10.1002/glia.23001 · Cited by 221
P2X7 Interactions and Signaling – Making Head or Tail of It
Kopp, R., Krautloher, A., Ramírez-Fernández, A., & Nicke, A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00183 · Cited by 217
Neuronal P2X7 Receptors Revisited: Do They Really Exist?
Illes, P., Khan, T. M., & Rubini, P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3103-16.2017 · Cited by 179
The P2X7 Receptor-Interleukin-1 Liaison
Giuliani, A. L., Sarti, A. C., Falzoni, S., & Di Virgilio, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00123 · Cited by 166
“Several studies show that P2X7R blockade efficiently antagonize IL-1β release in different disease experimental models (Bartlett et al., 2014).”
BackgroundThe P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
P2X7 on Mouse T Cells: One Channel, Many Functions
Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F., & Adriouch, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00204 · Cited by 116
Recent advances in CNS P2X7 physiology and pharmacology: Focus on neuropsychiatric disorders
Bhattacharya, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00030 · Cited by 115
Mechanism of microglia neuroprotection: Involvement of P2X 7,TNF α, and valproic acid
Masuch, A., Shieh, C., van Rooijen, N., van Calker, D., & Biber, K. (2016) · Glia · doi:10.1002/glia.22904 · Cited by 81
Role of P2X7 Receptors in Immune Responses During Neurodegeneration
Oliveira-Giacomelli, Á., Petiz, L. L., Andrejew, R., Turrini, N., Silva, J. B., Sack, U., & Ulrich, H. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.662935 · Cited by 68
Metzger, M. W., Walser, S. M., Dedic, N., Aprile-Garcia, F., Jakubcakova, V., Adamczyk, M., Webb, K. J., Uhr, M., Refojo, D., Schmidt, M. V., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3487-16.2017 · Cited by 59
Deletion of P2X7 attenuates hyperoxia-induced acute lung injury via inflammasome suppression
Galam, L., Rajan, A., Failla, A., Soundararajan, R., Lockey, R. F., & Kolliputi, N. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00417.2015 · Cited by 52
Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
Pleiotropic Roles of P2X7 in the Central Nervous System
Kanellopoulos, J. M., & Delarasse, C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00401 · Cited by 48
Gürsel (2018) · doi:10.1016/j.neubiorev.2018.02.005 · Cited by 47
Paroxetine suppresses recombinant human P2X7 responses
Dao-Ung, P., Skarratt, K. K., Fuller, S. J., & Stokes, L. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9467-2 · Cited by 29
Self-citationEROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling
Randzavola, L. O., Mortimer, P. M., Garside, E., Dufficy, E. R., Schejtman, A., Roumelioti, G., Yu, L., Pardo, M., Spirohn, K., Tolley, C., et al. (2022) · eLife · doi:10.7554/elife.76387 · Cited by 24
Metadata
- Authors
- Bartlett, R., Stokes, L., & Sluyter, R.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 66
- Issue
- 3
- Pages
- 638-675
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2128767149
- Cited by
- 393
- References
- 345
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.